Phase 3 RCT in 214 Chinese patients with resected stage II-IIIB EGFR-mutated NSCLC: adjuvant aumolertinib improved disease-free survival vs placebo (HR 0.17; median not reached vs 19.42 months). Grade 3-4 raised creatine phosphokinase in 7% vs none.
RCTn = 214
Zhang et al. Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial